Advertisement

Investigational New Drugs

, Volume 22, Issue 1, pp 63–68 | Cite as

Treatment of AIDS Related Non-Hodgkin's Lymphoma with Combination Mitoguazone Dihydrochloride and Low Dose Chop Chemotherapy: Results of a Phase II study

  • Anil Tulpule
  • Byron M. Espina
  • A. B. Pedro Santabarbara
  • Maria Palmer
  • Joanne Schiflett
  • William Boswell
  • Susan Smith
  • Alexandra M. Levine
Article

Abstract

Purpose: To evaluate the response and side effects of combination therapy with low dose CHOP chemotherapy and mitoguazone dihydrochloride in patients with non-Hodgkin's lymphoma associated with the acquired immunodeficiency syndrome (AIDS-NHL). Methods: Eighteen patients newly diagnosed with intermediate or high-grade AIDS-NHL were treated with low dose CHOP as follows: day 1, cyclophosphamide 350mg/m2, intravenously (IV); doxorubicin 25mg/m2 IV; vincristine 2mg IV; and prednisone 100mg given orally on days 1 through 5. In addition, mitoguazone dihydrochloride was given at a dose of 600mg/m2 IV on days 1 and 15 of each 28-day treatment cycle. Results: Seventeen males and one female patient were accrued. Twelve patients had high-grade pathologies while the remainder had an intermediate grade pathology (diffuse large cell). The median CD4+ lymphocyte count was 98/dl (range 1–924). Three patients (17%) reported an AIDS-defining illness prior to lymphoma diagnosis. Of 14 evaluable patients, 6 (43%) achieved a complete remission and 5 (35%) a partial remission. The median failure free and overall survival times were 6.5 and 8.4 months, respectively. Major toxicity was hematologic with grade 3 or 4 neutropenia in 72%; two patients died of neutropenic sepsis. Conclusions: Mitoguazone in combination with low dose CHOP is a safe regimen, associated with a response rate of 79% (CR 43%, PR 36%, 95% CI=49–95%). These preliminary results suggest no major improvement in terms of response over use of CHOP without mitoguazone.

HIV AIDS lymphoma NHL MGBG mitoguazone dihydrochloride CHOP 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Centers for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reported: United States. Ann Intern Med 103: 402–403, 1985Google Scholar
  2. 2.
    Beral V, Peterman T, Berkelman R, Jaffe H: AIDS associated non-Hodgkin's lymphoma. Lancet 337: 805–809, 1991Google Scholar
  3. 3.
    Pluda JM, Yarchoan R, Jaffe ES et al.: Development of non-Hodgkin's lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long term antiretroviral therapy. Ann Intern Med 113: 276, 1990Google Scholar
  4. 4.
    Ziegler JL, Beckstead JA, Volberding PA et al.: Non-Hodgkin's lymphomas in 90 homosexual men: Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 311: 565–570, 1984Google Scholar
  5. 5.
    Levine AM: AIDS-related lymphoma. Blood 80: 8–20, 1992Google Scholar
  6. 6.
    Levine AM, Wernz JC, Kaplan L et al.: Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 226: 84–88, 1991Google Scholar
  7. 7.
    Kaplan L, Straus D, Testa M et al.: Low-dose compared with standard-dose mBACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 23: 1641–1648, 1997Google Scholar
  8. 8.
    Sparano JA, Wiernik PH, Hu Xiaoping et al.: Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastrim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 14: 3026–3035, 1996Google Scholar
  9. 9.
    Warrell RP, Burchenal JH: Methylglyoxal-bis(guanylhydrazone) (methyl-GAG): Current studies and future prospects. J Clin Oncol 1: 52–65, 1983Google Scholar
  10. 10.
    Levine AM, Tulpule A, Tessman D et al.: Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter Phase II Trial. J Clin Oncol 15: 1094–1103, 1997Google Scholar
  11. 11.
    Rizzo J, Levine A, Weiss GR et al.: Pharmacokinetic profile of mitoguazone (MGBG) in patients with AIDS-related non-Hodgkin's lymphoma. Invest New Drugs 14: 227–234, 1996Google Scholar
  12. 12.
    Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239–253, 1992Google Scholar
  13. 13.
    Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York 1980Google Scholar
  14. 14.
    Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc 78: 427–434, 1983Google Scholar
  15. 15.
    Minitab Reference Manual. PC Version, Release 8. (PA): Minitab Inc, State College, PA, 1991Google Scholar
  16. 16.
    Gill PS, Levine AM, Krailo M et al.: AIDS-related malignant lymphoma: Results of prospective treatment trials. J Clin Oncol 5: 1322–1328, 1987Google Scholar
  17. 17.
    Levine AM, Sullivan-Halley J, Pike MC et al.: Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 68: 2466–2472, 1991Google Scholar
  18. 18.
    Gisselbrecht C, Oksenhendler E, Tirelli U et al.: Human immunodeficiency virus-related lymphoma treated with intensive combination chemotherapy. Am J Med 95: 188–196, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Anil Tulpule
    • 1
  • Byron M. Espina
    • 1
  • A. B. Pedro Santabarbara
    • 1
  • Maria Palmer
    • 1
  • Joanne Schiflett
    • 1
  • William Boswell
    • 1
  • Susan Smith
    • 1
  • Alexandra M. Levine
    • 1
  1. 1.Department of Medicine and RadiologyUniversity of Southern California Medical Center, Norris Cancer Hospital and Research InstituteLos AngelesU.S.A.

Personalised recommendations